EUVIMEDEUVIMED entdecken
Crossref

Safety and efficacy of DOACs for non-cirrhotic splanchnic vein thrombosis: a single centre retrospective analysis

Luca Depietri, Filippo B Fabbri, Maria Rosaria Veropalumbo, Eleonora Spaggiari, Sara Corradini, Maria Cristina Leone, Annamaria Casali, Matteo Iotti

European Journal of Clinical Pharmacology · 2026

DOI: 10.1007/s00228-025-03966-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Luca Depietri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Specialized in Metabolic and Coagulation Disorders - Angiology Unit, AUSL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reg…. Hauptthemen laut MEDLINE: Venous Thrombosis, Anticoagulants, Factor Xa Inhibitors. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In recent years, increasing evidence has emerged regarding the use of direct oral anticoagulants (DOACs) for the treatment of splanchnic vein thrombosis (SVT) in non-cirrhotic patients. However, available data are predominantly retrospective, derived from small and heterogeneous cohorts; consequently, the use of DOACs for this indication remains off-label. METHODS: To further evaluate the safety and efficacy of DOACs in this setting, 21 consecutive patients with acute non-cirrhotic SVT were enrolled and treated with DOACs for a minimum of 6 months. RESULTS: No cases of SVT progression, recurrence, or major bleeding were observed during follow-up. One patient experienced a minor bleeding event. CONCLUSIONS: These findings are consistent with previous reports indicating a favorable safety profile of DOACs, with a low risk of bleeding. However, conclusions regarding efficacy remain uncertain, precluding definitive inferences on their effectiveness in non-cirrhotic SVT. Larger, well-designed prospective studies are required to clarify the true efficacy of DOACs in this clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThrombosisAnticoagulantsFactor Xa InhibitorsHumansRetrospective StudiesFemaleMaleAgedMiddle AgedSplanchnic CirculationHemorrhageTreatment OutcomeAged, 80 and overAdministration, Oral

Stichwörter der Autor:innen

Anticoagulant therapyDirect oral anticoagulants (DOACs)Mesenteric venous thrombosisPortal venous thrombosisSplanchnic venous thrombosisSplenic vein thrombosis

Substanzen

AnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Internal Medicine Specialized in Metabolic and Coagulation Disorders - Angiology Unit, AUSL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy. Luca.depietri@ausl.re.it.
  • Intermediate and High-Intensity Care Internal Medicine, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Internal Medicine Specialized in Metabolic and Coagulation Disorders - Angiology Unit, AUSL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy.

Zitieren

APA

Depietri, L., Fabbri, F. B., Veropalumbo, M. R., Spaggiari, E., Corradini, S., Leone, M. C., Casali, A., & Iotti, M. (2026). Safety and efficacy of DOACs for non-cirrhotic splanchnic vein thrombosis: a single centre retrospective analysis. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-025-03966-9

Vancouver

Depietri L, Fabbri FB, Veropalumbo MR, Spaggiari E, Corradini S, Leone MC, et al. Safety and efficacy of DOACs for non-cirrhotic splanchnic vein thrombosis: a single centre retrospective analysis. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-025-03966-9

BibTeX
@article{Depietri2026,
  author = {Depietri, Luca and Fabbri, Filippo B and Veropalumbo, Maria Rosaria and Spaggiari, Eleonora and Corradini, Sara and Leone, Maria Cristina and Casali, Annamaria and Iotti, Matteo},
  title = {Safety and efficacy of DOACs for non-cirrhotic splanchnic vein thrombosis: a single centre retrospective analysis},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1007/s00228-025-03966-9}
}
Kostenlos starten →